Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
Abstract This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT). Samples from healthcare workers who received vaccines against SARS-CoV-2 were tested for R...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-26202-1 |
| _version_ | 1797958743254630400 |
|---|---|
| author | Poramed Winichakoon Jiraprapa Wipasa Kriangkrai Chawansuntati Parichat Salee Tavitiya Sudjaritruk Saowaluck Yasri Chantana khamwan Rungnapa Peerakam Dararat Dankai Romanee Chaiwarith |
| author_facet | Poramed Winichakoon Jiraprapa Wipasa Kriangkrai Chawansuntati Parichat Salee Tavitiya Sudjaritruk Saowaluck Yasri Chantana khamwan Rungnapa Peerakam Dararat Dankai Romanee Chaiwarith |
| author_sort | Poramed Winichakoon |
| collection | DOAJ |
| description | Abstract This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT). Samples from healthcare workers who received vaccines against SARS-CoV-2 were tested for RBD-specific antibody, S-specific antibody, and in-house ELISA, commercial sVNT, and in-house sVNT, against wild-type SARS-CoV-2. Three hundred and five samples were included in the analysis. The correlation between S-specific binding antibodies and in-house ELISA was 0.96 (95% CI 0.96–0.97) and between RBD-specific antibodies and in-house ELISA was 0.96 (95% CI 0.95–0.97). The Cohen’s kappa between in-house sVNT and the commercial test was 0.90 (95% CI 0.80, 1.00). If using 90% inhibition of sVNT as the reference standard, the optimal cut-off value of RBD-specific antibodies was 442.7 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 99%, and 100%, respectively. The optimal cut-off value of S-specific antibodies was 1155.9 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 100%, and 99%, respectively. This study demonstrated a very strong correlation between in-house ELISA and 2 commercial assays. There was also a very strong correlation between in-house and commercial SARS-CoV-2 sVNT, a finding of particular interest which will inform future research. |
| first_indexed | 2024-04-11T00:23:08Z |
| format | Article |
| id | doaj.art-9c565bd4db2b4ba488571ee488e167d9 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T00:23:08Z |
| publishDate | 2023-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-9c565bd4db2b4ba488571ee488e167d92023-01-08T12:10:56ZengNature PortfolioScientific Reports2045-23222023-01-011311910.1038/s41598-022-26202-1Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)Poramed Winichakoon0Jiraprapa Wipasa1Kriangkrai Chawansuntati2Parichat Salee3Tavitiya Sudjaritruk4Saowaluck Yasri5Chantana khamwan6Rungnapa Peerakam7Dararat Dankai8Romanee Chaiwarith9Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityResearch Institute for Health Sciences, Chiang Mai UniversityResearch Institute for Health Sciences, Chiang Mai UniversityDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai UniversityDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityDiagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai UniversityDiagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai UniversityDiagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai UniversityDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityAbstract This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT). Samples from healthcare workers who received vaccines against SARS-CoV-2 were tested for RBD-specific antibody, S-specific antibody, and in-house ELISA, commercial sVNT, and in-house sVNT, against wild-type SARS-CoV-2. Three hundred and five samples were included in the analysis. The correlation between S-specific binding antibodies and in-house ELISA was 0.96 (95% CI 0.96–0.97) and between RBD-specific antibodies and in-house ELISA was 0.96 (95% CI 0.95–0.97). The Cohen’s kappa between in-house sVNT and the commercial test was 0.90 (95% CI 0.80, 1.00). If using 90% inhibition of sVNT as the reference standard, the optimal cut-off value of RBD-specific antibodies was 442.7 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 99%, and 100%, respectively. The optimal cut-off value of S-specific antibodies was 1155.9 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 100%, and 99%, respectively. This study demonstrated a very strong correlation between in-house ELISA and 2 commercial assays. There was also a very strong correlation between in-house and commercial SARS-CoV-2 sVNT, a finding of particular interest which will inform future research.https://doi.org/10.1038/s41598-022-26202-1 |
| spellingShingle | Poramed Winichakoon Jiraprapa Wipasa Kriangkrai Chawansuntati Parichat Salee Tavitiya Sudjaritruk Saowaluck Yasri Chantana khamwan Rungnapa Peerakam Dararat Dankai Romanee Chaiwarith Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) Scientific Reports |
| title | Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) |
| title_full | Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) |
| title_fullStr | Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) |
| title_full_unstemmed | Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) |
| title_short | Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) |
| title_sort | diagnostic performance between in house and commercial sars cov 2 serological immunoassays including binding specific antibody and surrogate virus neutralization test svnt |
| url | https://doi.org/10.1038/s41598-022-26202-1 |
| work_keys_str_mv | AT poramedwinichakoon diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT jiraprapawipasa diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT kriangkraichawansuntati diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT parichatsalee diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT tavitiyasudjaritruk diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT saowaluckyasri diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT chantanakhamwan diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT rungnapapeerakam diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT dararatdankai diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt AT romaneechaiwarith diagnosticperformancebetweeninhouseandcommercialsarscov2serologicalimmunoassaysincludingbindingspecificantibodyandsurrogatevirusneutralizationtestsvnt |